# Milbeguard Duo 25 mg / 250 mg chewable tablets for large dogs

Authorised

- Milbemycin oxime
- Praziquantel

## Product identification

**Medicine name:**
Milbeguard Duo 25 mg / 250 mg chewable tablets for large dogs
Milbeguard Duo 25 mg / 250 mg chewable tablets for large dogs

**Active substance:**
Milbemycin oxime
Praziquantel

**Target species:**
Dog

**Route of administration:**
Oral use

## Product details

**Active substance and strength:**
Milbemycin oxime
25.00 milligram(s) / 1.00 Tablet

Praziquantel
250.00 milligram(s) / 1.00 Tablet

**Pharmaceutical form:**
Chewable tablet

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**
QP54AB51

**Legal status of supply:**
Veterinary medicinal product subject to veterinary prescription

**Authorisation status:**
Valid

**Authorised in:**
Ireland

**Package description:**
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 50 blisters of 2 tablets (100 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 24 blisters of 2 tablets (48 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 12 blisters of 2 tablets (24 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 5 blisters of 2 tablets (10 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 2 blisters of 2 tablets (4 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 1 blister of 2 tablets (2 tablets).

## Additional information

**Entitlement type:**
Marketing Authorisation

**Legal basis of product authorisation:**

Hybrid application – change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)

**Marketing authorisation holder:**
Ceva Sante Animale

**Marketing authorisation date:**
19/01/2024

**Manufacturing sites for batch release:**
Ceva Sante Animale

**Responsible authority:**
Health Products Regulatory Authority

**Authorisation number:**
VPA10815/067/003

**Date of authorisation status change:**
19/01/2024

**Reference member state:**
Ireland

**Procedure number:**
IE/V/0780/003

**Concerned member states:**
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

## Documents

Combined File of all Documents

Summary of Product Characteristics